宽QRS波对高血压患者合并左心室肥厚严重程度的预测价值

摘要/Abstract

摘要： 左心室肥厚（left ventricular hypertrophy, LVH）是高血压患者心血管病死率和发病率的一个重要危险因素,LVH的严重程度与更高的心血管疾病患病率和更高的死亡风险相关。心电图作为检测LVH的常用工具,电压标准为诊断左心室肥厚的常用标准,QRS波在其中充当重要角色,QRS波时限提高了诊断的准确性,现就宽QRS波机制、影响因素、应用价值等在预测高血压患者左心室肥厚程度方面的研究进展作一综述。

关键词: 左心室肥厚, 高血压, 高血压心脏病, QRS波时限

黄雪枝, 陆兆华. 宽QRS波对高血压患者合并左心室肥厚严重程度的预测价值[J]. 心血管病防治知识, 2026, 16(2): 141-144.

参考文献

[1] Naderi H, Ramírez J, Van Duijvenboden S, et al.Diagnostic and prognostic value of ECG-predicted hypertension-mediated left ventricular hypertrophy using machine learning[J]. J Hypertens, 2025,43(8):1327-1338.
[2] 刘明波,何新叶,杨晓红,等.《中国心血管健康与疾病报告2024》高血压章节要点解读[J].中华高血压杂志(中英文),2025,33(12):1138-1141.
[3] Roush GC, Abdelfattah R, Song S, et al.Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis[J]. J Clin Hypertens (Greenwich), 2018,20(10): 1507-1515.
[4] Bacharova L.Missing Link between Molecular Aspects of Ventricular Arrhythmias and QRS Complex Morphology in Left Ventricular Hypertrophy[J]. Int J Mol Sci, 2019,21(1):48.
[5] Leache L, Gutiérrez-Valencia M, Finizola RM, et al. Pharmacotherapy for hypertension-induced left ventricular hypertrophy[J]. Cochrane Database Syst Rev, 2021, 10(10): CD012039.
[6] 束长城,魏万林.高血压左心室肥厚的形成机制研究进展[J].中国循证心血管医学杂志,2018,10(6):760-762.
[7] Raina R, Khooblall A, Shah R, et al.Cardiovascular implications in adolescent and young adult hypertension[J]. Rev Cardiovasc Med, 2022, 23(5): 166.
[8] Aronow WS.Hypertension and left ventricular hypertrophy[J]. Ann Transl Med,2017,5(15):310.
[9] Slivnick J, Lampert BC.Hypertension and Heart Failure[J]. Heart Fail Clin, 2019,15(4): 531-541.
[10] Messerli FH, Rimoldi SF, Bangalore S.The Transition From Hypertension to Heart Failure: Contemporary Update[J]. JACC Heart Fail,2017, 5(8): 543-551.
[11] 童瑶,李芳卉,李文韬,等.高血压与心律失常相关性研究的进展[J].心血管康复医学杂志,2022,31(4):485-489.
[12] 邓兆敏,朱情情,王媚媚,等.老年高血压患者左心室肥厚与心律失常及心率变异性的相关性[J].吉林医学,2023,44(10):2774-2776.
[13] Chaudhary KW, Clancy CE, Yang PC, et al.An overview of drug-induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety[J]. Clin Transl Sci, 2024,17(12): e70098.
[14] Domain G, Chouquet C, Réant P, et al.Relationships between left ventricular mass and QRS duration in diverse types of left ventricular hypertrophy[J]. Eur Heart J Cardiovasc Imaging, 2022,23(4): 560-568.
[15] DeBauge A, Fairbank T, Harvey CJ, et al. Electrocardiographic prediction of left ventricular hypertrophy in women and men with left bundle branch block - Comparison of QRS duration, amplitude and voltage-time-integral[J]. J Electrocardiol, 2023,80: 34-39.
[16] Tadic M, Cuspidi C.Cuspidi, Electrocardiographic criteria for cardiac remodeling in hypertensive patients[J]. J Clin Hypertens (Greenwich), 2019. 21(3): 379-381.
[17] 马志玲,赵志敬,耶闯,等.高血压所致左心室肥厚与肥厚型心肌病体表心电图和超声心动图的鉴别要点[J].心脏杂志,2019,31(3):295-301.
[18] Petersen SS, Pedersen LR, Pareek M, et al.Factors associated with diagnostic discrepancy for left ventricular hypertrophy between electrocardiography and echocardiography[J]. Blood Press, 2017, 26(1): 54-63.
[19] Lieb W, Xanthakis V, Sullivan LM, et al.Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the framingham offspring study[J]. Circulation, 2009. 119(24): 3085-3092.
[20] Cai S, Dong J, Cheng B, et al.Relationship of a new anthropometric index with left ventricular hypertrophy in hypertensive patients among the Han Chinese[J]. BMC Cardiovasc Disord, 2022, 22(1): 16.
[21] Rodrigues JC, McIntyre B, Dastidar AG, et al., The effect of obesity on electrocardiographic detection of hypertensive left ventricular hypertrophy: recalibration against cardiac magnetic resonance[J]. J Hum Hypertens, 2016, 30(3): 197-203.
[22] Nomsawadi V, Krittayaphong R.Diagnostic performance of electrocardiographic criteria for left ventricular hypertrophy among various body mass index groups compared to diagnosis by cardiac magnetic resonance imaging[J]. Ann Noninvasive Electrocardiol, 2019, 24(4): e12635.
[23] Yontar OC, Yilmaz MB, Yalta K, et al.Acute effects of levosimendan and dobutamine on QRS duration in patients with heart failure[J]. Arq Bras Cardiol, 2010,95(6): 738-42.